CDK13 Polyklonaler Antikörper

CDK13 Polyklonal Antikörper für WB, IHC, IF/ICC, FC (Intra), ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human

Anwendung

WB, IHC, IF/ICC, FC (Intra), ELISA

Konjugation

Unkonjugiert

Publikationen(2)

Kat-Nr. : 30461-1-AP

Synonyme

CDC2L5, CHED, CDC2L, CDC2 related protein kinase 5

---

• 

  WB analysis using 30461-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 30461-1-AP (CDK13 antibody) at dilution of 1:800 incubated at room temperature for 1.5 hours.

• 

  IHC staining of human ovary cancer using 30461-1-AP

  Immunohistochemical analysis of paraffin-embedded human ovary cancer tissue slide using 30461-1-AP (CDK13 antibody) at dilution of 1:200 (under 20x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IF Staining of HeLa using 30461-1-AP

  Immunofluorescent analysis of (4% PFA) fixed HeLa cells using CDK13 antibody (30461-1-AP) at dilution of 1:400 and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L), CL594-phalloidin (red).

• 

  FC experiment of K-562 using 30461-1-AP

  1X10^6 K-562 cells were intracellularly stained with 0.4 ug Anti-Human CDK13 (30461-1-AP) and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L) at dilution 1:1000 (red), or 0.4 ug Isotype Control. Cells were fixed and permeabilized with Transcription Factor Staining Buffer Kit (PF00011).

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in WB: HEK-293T-Zellen, HeLa-Zellen, Jurkat-Zellen, MDA-MB-468-Zellen
• Erfolgreiche Detektion in IHC: human ovary cancer tissue; Hinweis: Antigendemaskierung mit TE-Puffer pH 9,0 empfohlen. (*) Wahlweise kann die Antigendemaskierung auch mit Citratpuffer pH 6,0 erfolgen.
• Erfolgreiche Detektion in IF/ICC: HeLa-Zellen
• Erfolgreiche Detektion in FC (Intra): K-562-Zellen

Empfohlene Verdünnung

• Western Blot (WB): WB : 1:500-1:1000
• Immunhistochemie (IHC): IHC : 1:50-1:500
• Immunfluoreszenz (IF)/ICC: IF/ICC : 1:200-1:800
• Durchflusszytometrie (FC) (INTRA): FC (INTRA) : 0.40 ug per 10^6 cells in a 100 µl suspension

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Veröffentlichte Anwendungen

• WB: See 2 publications below

Produktinformation

30461-1-AP bindet in WB, IHC, IF/ICC, FC (Intra), ELISA CDK13 und zeigt Reaktivität mit human

• Getestete Reaktivität: human
• In Publikationen genannte Reaktivität: human
• Wirt / Isotyp: Kaninchen / IgG
• Klonalität: Polyklonal
• Typ: Antikörper
• Immunogen: CDK13 fusion protein Ag32897
• Vollständiger Name: cell division cycle 2-like 5 (cholinesterase-related cell division controller)
• Berechnetes Molekulargewicht: 165 kDa
• Beobachtetes Molekulargewicht: 170 kDa
• GenBank-Zugangsnummer: NM_003718.4
• Gene symbol: CDK13
• Gene ID (NCBI): 8621
• Konjugation: Unkonjugiert
• Form: Liquid
• Reinigungsmethode: Antigen-Affinitätsreinigung
• Lagerungspuffer: PBS with 0.02% sodium azide and 50% glycerol
• Lagerungsbedingungen: Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

Cyclin-dependent kinase 13 (CDK13) is also named as CDC2L, CDC2L5, CHED and KIAA1791, and belongs to the CMGC Ser/Thr protein kinase family. Interestingly, in TNBC cells silencing CDK13 provokes cell death without affecting DDR genes. Like CDK12, CDK13 phosphorylates the Ser2 position of the heptad repeat in the CTD of RNA Pol II (PMID:26748711). CDK13/CycK complex is that regulates transcription by phosphorylating serine residues at positions 5 and 2 of the heptapeptide repeats (Y-S-P-T-S-P-S) comprising the C-terminal domain (CTD) of RPB1, the largest subunit of RNA polymerase II (RNAPII). CDK13 is expressed in fetal brain, liver, and muscle, and adult whole brain, hippocampus, and bone marrow (PMID:30904094).

Publikationen

Species	Application	Title
human	WB	Carcinogenesis; CDK12 is a promising therapeutic target for the transcription cycle and DNA damage response in metastatic osteosarcoma; Authors - Zihao Li
human	WB	J Med Chem; Identification of a Potent and Selective CDK9 Degrader as a Targeted Therapeutic Option for the Treatment of Small-Cell Lung Cancer; Authors - Yubo Wang